Pancreatic Cancer Research

ResearcherNational Taiwan UniversityNo recent work listed

Yung‐Ming Jeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3878-4491; OpenAlex author ID A5041457441. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 8

  1. Pancreatic cancer-derived small extracellular vesical ezrin activates fibroblasts to exacerbate cancer metastasis through STAT3 and YAP-1 signaling pathways. Co-author DOI 10.1002/1878-0261.13442↗
  2. Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.abc2823↗
  3. Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis. Last author PMID 32064151↗
  4. Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocar… Co-author DOI 10.1007/s00259-018-4251-5↗
  5. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. Co-author PMID 30662811↗
  6. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Last author PMID 28337383↗
  7. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2015.248260↗
  8. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. Co-author DOI 10.1084/jem.20141702↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu‐Ting Chang · 6 shared papers, 2016–2023 · strength 0.65
  2. Chun‐Mei Hu · 4 shared papers, 2018–2023 · strength 0.52
  3. Ming‐Chu Chang · 5 shared papers, 2016–2023 · strength 0.51
  4. Yu‐Wen Tien · 5 shared papers, 2015–2021 · strength 0.37
  5. Sui-Chih Tien · 2 shared papers, 2020–2023 · strength 0.34
  6. Hsuan‐Yu Peng · 2 shared papers, 2020–2023 · strength 0.34
  7. Wen‐Hwa Lee · 4 shared papers, 2015–2021 · strength 0.28
  8. Y.M. Chen · 2 shared papers, 2018–2021 · strength 0.18
  9. Heng‐Hsiung Wu · 2 shared papers, 2015–2021 · strength 0.16
  10. Shih‐Hung Yang · 2 shared papers, 2016–2017 · strength 0.12
  11. Lung‐Hung Tsai · 1 shared paper, 2021 · strength 0.11
  12. Chia‐Ning Shen · 1 shared paper, 2021 · strength 0.11
  13. Mei‐Fang Cheng · 1 shared paper, 2019 · strength 0.09
  14. Ting‐Chun Kuo · 1 shared paper, 2019 · strength 0.09
  15. Bang‐Bin Chen · 1 shared paper, 2017 · strength 0.07
  16. Po‐Chin Liang · 1 shared paper, 2017 · strength 0.07
  17. Chih‐Horng Wu · 1 shared paper, 2017 · strength 0.07
  18. I‐Shiow Jan · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.